“There seems to be a growing interest in humans to treat covid-1 with a drug called ivimectin. Evermectin is frequently used in the United States to treat or prevent parasites in animals. The FDA has received numerous reports of patients in need of medical assistance and for horses.” Have been hospitalized after self-medicating with ivermectin, ”the agency said in a statement on Friday.
The declaration notes that the FDA has not approved ivermectin to treat or prevent covid-19 in humans and that the drug is not an anti-viral drug.
“Taking large doses of this drug is dangerous and can cause serious harm,” the announcement said, adding that levels of ivermectin approved for other uses could also interact with other drugs, such as blood thinners.
“You can also overdose on ivermectin, which can cause nausea, vomiting, diarrhea, hypotension (low blood pressure), allergic reactions (itching and hives), dizziness, ataxia (balance problems), seizures, coma and even death. . “
In the JAMA study in Cali, Colombia, about 600 adults with mild disease who had symptoms for seven days volunteered to help with drug testing. The trial is known as the double-blind randomized controlled trial, the gold-standard of trial.
Half of the volunteers received the drug for five days, the other half received placebo and standard care. Patients were enrolled in the trial, which ran between July 2020 and November 2020, and Dr. Cutter chased them with them in December.
At the end of the hearing, both groups of volunteers had almost the same number of adverse events – mostly headaches -. Patients receiving the drug reported that their symptoms subsided in 10 days. For the placebo receiving group, it was 12 days.
The two days were not considered a “significant” improvement.
“The findings do not support the use of Ivermectin for the treatment of mild COVID-19,” the Colombia-based researcher wrote. The study adds that larger tests may be needed to better understand if ivermectin provides any other type of benefit for Covid-19 patients. In this case, the study focuses on symptoms and mild disease.
.
